- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Peptic ulcers respond to acid-reducer medications
PPIs and H2 -receptor blockers are standard treatment for peptic ulcers and GERD, but lifestyle changes and OTC products can help
Peptic ulcer disease affects 10% of men and 4% of women in the United States at some point in their lives. The two most common causes are the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and infection with Helicobacterpylori (H. pylori) bacteria.
The primary treatments for peptic ulcers are medications that suppress the flow of gastric acid, together with antibiotics to eradicate H. pylori.
The first step is to find out whether H. pylori is present. A number of different tests are used, including the urea breath test, stool antigen test and an endoscopic biopsy. The standard treatment for this bacteria includes various combinations of two or three antimicrobial drugs.
In general, gastroenterologists are aware of the need to test for H. pylori and treat it appropriately, says Michael J. Tocco, RPh, MEd, president of Integrated Pharmacy Solutions Inc. in Stoneham, Mass.
"General practitioners today are often not as aggressive in seeking and treating H. pylori, especially in the elderly," he says. "The prevalence of this bacteria increases with age, so testing and treating elderly patients is essential."
A decade ago, Tocco was part of the team at the Institute of Contemporary Pharmacy Research that developed a consensus pharmacotherapy algorithm on the treatment of H. pylori.
"PPIs heal peptic ulcers more rapidly than H2-blockers or any other drug. Prilosec (omeprazole) generally is as effective as any other PPI, and is available generically and over the counter," says Dr. Abramowicz.
H2-blockers are available over the counter and inhibit 50% to 80% of acid secretion. Continuous administration of H2-blockers does lead to pharmacologic tolerance and decreased effectiveness over time.
"Among H2-blockers, the low price of generic cimetidine probably does not outweigh its many adverse drug interactions," says Dr. Abramowicz.
Gastroesophageal reflux disease (GERD), which is the chronic reflux of acid into the esophagus, can lead to esophagitis, esophageal ulcers, and changes in the lining of the esophagus that increase the risk of developing cancer. Medical therapy for GERD is based on acid suppression. H2-blockers and antacids are used for patients with mild, intermittent symptoms, while treatment with a PPI is preferred for those with more severe disease.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
